NLRP3 inflammasome activation drives tau pathology.

Nature. 2019 Nov;575(7784):669-673.

Ising C^1,2 , Venegas C¹, Zhang S^1,2, Scheiblich H^1,2, Schmidt SV³, Vieira-Saecker A^1,2, Schwartz S^1,2, Albasset S^1,2, McManus RM^1,2, Tejera D², Griep A², Santarelli F², Brosseron F², Opitz S^1,2, Stunden J⁴, Merten M¹, Kayed R⁵, Golenbock DT⁶, Blum D⁷, Latz E^2,3,6, Buée L⁷, Heneka MT^8,9,10.

1. Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.
2. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
3. Institute of Innate Immunity, University Hospital Bonn, Bonn, Germany.
4. IFM Therapeutics GmbH, Bonn, Germany.
5. Mitchell Center for Neurodegenerative Diseases and Departments of Neurology, Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA.
6. Divison of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA.
7. University of Lille, Inserm, CHU-Lille, UMR-S 1172, "Alzheimer & Tauopathies", Labex DISTALZ, Lille, France.
8. Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany. michael.heneka@ukbonn.de.
9. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. michael.heneka@ukbonn.de.
10. Divison of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA. michael.heneka@ukbonn.de.

Presented by Christina Ising